QUEBEC CITY, Sept. 12 /CNW Telbec/ - Advitech Inc. (“Advitech” or the “Corporation”) (TSX Venture Exchange: AVI) announced today that a post-marketing study conducted on patients suffering from psoriasis shows that the use of Dermylex(TM) may benefit patients already using topical corticosteroids. Using Dermylex(TM) with topical corticosteroids may create a synergistic effect and improve overall treatment efficacy results. Therefore, Dermylex(TM) might act as an adjuvant to topical corticosteroids.
